Review
Open access
Aug 2026
Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1
This review delineates the principal neoadjuvant immunotherapy biomarkers implicated in breast cancer and elucidate their action mechanisms and summarizes the ongoing and reported clinical studies to offer a coherent perspective on the evolving role of neoadjuvant immunotherapy in breast cancer management.
Zi-Wei Zhang, Renjie Zhao, Yuan Hu et al.
· Frontiers in Immunology · 0 citations